Figure 1. Hypothetical successful treatment with omalizumab in a severe asthma cohort. 434 severe asthma patients were stratified for hypothetical eligibility for omalizumab treatments based on atopic status [at least one specific allergen result ≥ 0.35 kU/L from ALT. ALTERNATA, CAT DANDER, COCKROACH,, D. FARINAE, D. PTERONYSSINUS, DOG DANDER and additional panel of allergens dependent on country (Table S1)], IgE/bodyweight eligibility (based on US dosing table; Table S2) and responder status after 16 wk by physician’s global assessment (based on responder rate of 61% in Bousquet et al. 2007¹²)